Viewing Study NCT02870569


Ignite Creation Date: 2025-12-24 @ 10:58 PM
Ignite Modification Date: 2026-04-21 @ 11:54 AM
Study NCT ID: NCT02870569
Status: COMPLETED
Last Update Posted: 2019-03-01
First Post: 2016-08-12
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module